Sex and anti-inflammatory treatment affect outcome of melanoma and non-small cell lung cancer patients with rheumatic immune-related adverse events

Gente, Karolina; Diekmann, Leonore; Daniello, Lea; Will, Julia; Feisst, Manuel; Olsavszky, Victor; Günther, Janine; Lorenz, Hanns-Martin; Souto-Carneiro, M Margarida; Hassel, Jessica C; Christopoulos, Petros; Leipe, Jan

doi:10.1136/jitc-2023-007557

Cited by 3 publications

(1 citation statement)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immune checkpoint inhibitors (ICIs) enhance T-cell-mediated anti-tumor responses by targeting immune regulatory molecules such as cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed death-1 (PD-1) and its ligand, PD-L1, and are effective against a variety of advanced malignancies [1]. Immune checkpoints are involved in maintaining the homeostasis of immune responses and are deeply involved in peripheral tolerance and the autoimmune diseases caused by its breakdown [2].…”

Section: Introductionmentioning

confidence: 99%

Pituitary-Related Adverse Events and Onset Patterns Caused by Immune Checkpoint Inhibitors: Analysis Using the Japanese Adverse Drug Event Report Database

Asano,

Noguchi,

Kimura

et al. 2023

Medicina

View full text Add to dashboard Cite

Background and Objectives: One type of immune-related adverse event caused by immune checkpoint inhibitors (ICIs) is pituitary-related adverse events. The management of pituitary-related adverse events is important because they can be fatal if not treated promptly. Therefore, this study was conducted to investigate the onset of pituitary-related adverse events using the Japanese Adverse Drug Report (JADER) database. Materials and Methods: Cases registered in the JADER database from 2004 to 2019 were used. The target drugs were ipilimumab, nivolumab, pembrolizumab, avelumab, atezolizumab, and durvalumab, and the target adverse events were the high-level terms “Anterior pituitary hypofunction,” “Anterior pituitary hyperfunction,” “Posterior pituitary disorder,” and “Pituitary neoplasm” in the Medical Dictionary for Regulatory Activities, Japanese version (MedDRA/J). The information component (IC) was used for signal detection and IC delta (ICΔ) was used for women-related signals. Onset timing and patterns were analyzed using the Weibull distribution. Results: Signals were detected with ipilimumab, nivolumab, pembrolizumab, and atezolizumab in “Anterior pituitary hypofunction,” with ICs and 95% credible intervals (95%CrI) of 5.53 (5.30–5.69), 4.96 (4.79–5.08), 4.04 (3.76–4.25), and 2.40 (1.53–3.00). Significant signals were detected in women, except for atezolizumab. Additionally, the time of onset was classified as the wear-out failure type. Inverse signals were detected with ipilimumab and nivolumab in “Posterior pituitary disorder,” with ICs (95%CrI) of −1.24 (−2.80–−0.26), and −0.89 (−1.64–−0.37). Conclusions: Anterior pituitary hypofunction is likely to occur with the long-term administration of ipilimumab, nivolumab, and pembrolizumab. Further investigation is needed to determine the differences in the tendencies to detect signals in the anterior and posterior pituitaries between ipilimumab and nivolumab.

show abstract

Section: Introductionmentioning

confidence: 99%

Pituitary-Related Adverse Events and Onset Patterns Caused by Immune Checkpoint Inhibitors: Analysis Using the Japanese Adverse Drug Event Report Database

Asano,

Noguchi,

Kimura

et al. 2023

Medicina

View full text Add to dashboard Cite

show abstract

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma

Verheijden,

Burgers,

Janssen

et al. 2024

European Journal of Cancer

View full text Add to dashboard Cite

Management of Rheumatologic Immune-Related Adverse Events (Rh-irAEs) – An Overview of Immunosuppressive Therapies

Jamal,

Li,

Hudson

et al. 2024

Can Rheumatol Today

View full text Add to dashboard Cite

Cancer treatment has entered a new era with the expanding role of immunotherapy, in particular immune checkpoint inhibitors (ICIs). ICIs, including those that target cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed death protein-1 (PD-1), and programmed death ligand-1 (PD-L1), work by blocking the intrinsic down-regulators of the immune system, leading to sustained activation of effector T-cells to enhance endogenous anti-tumour immune responses.

show abstract

Sex and anti-inflammatory treatment affect outcome of melanoma and non-small cell lung cancer patients with rheumatic immune-related adverse events

Cited by 3 publications

References 56 publications

Pituitary-Related Adverse Events and Onset Patterns Caused by Immune Checkpoint Inhibitors: Analysis Using the Japanese Adverse Drug Event Report Database

Pituitary-Related Adverse Events and Onset Patterns Caused by Immune Checkpoint Inhibitors: Analysis Using the Japanese Adverse Drug Event Report Database

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma

Management of Rheumatologic Immune-Related Adverse Events (Rh-irAEs) – An Overview of Immunosuppressive Therapies

Contact Info

Product

Resources

About